文献速递血管炎

ANCA相关性血管炎治疗并发症的综述

Complications of therapy for ANCA-associated vasculitis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本文综述ANCA相关性血管炎免疫抑制治疗相关并发症,指出感染是早期死亡主因,恶性肿瘤和心血管疾病为长期后遗症,强调糖皮质激素毒性及减量策略,并呼吁个体化治疗预测工具。

要点

  • 感染是ANCA相关性血管炎早期死亡的最主要原因。
  • 恶性肿瘤和心血管疾病是重要的长期后遗症。
  • 糖皮质激素毒性日益受重视,未来策略应聚焦减量或节约。

核心结论

  • 免疫抑制治疗使ANCA相关性血管炎从致死性疾病转为慢性复发性疾病,但疾病本身和治疗相关并发症仍影响多数患者。

研究设计与样本

  • 本文为综述,聚焦ANCA相关性血管炎常用免疫抑制治疗的并发症及预防监测策略。

主要发现

  • 感染而非未控制血管炎是早期死亡的最大原因,且此后仍是主要问题。
  • 恶性肿瘤和心血管疾病发生率增加是额外的长期重要后遗症。
  • 糖皮质激素对治疗毒性的贡献日益被认识。

临床怎么用

  • 临床需在免疫抑制降低复发风险与减少治疗不良反应之间取得平衡。
  • 未来治疗策略应集中于糖皮质激素最小化或节约策略。
  • 需开发可靠的个体未来临床病程预测指标以个体化调整治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of immunosuppressive therapies has transformed ANCA-associated vasculitis (AAV) from a largely fatal condition to a chronic relapsing disorder. However, progressive organ damage and disability, both from the disease process itself and from therapies used for treatment, eventually affect the majority of patients. Infection, rather than uncontrolled vasculitis, is the greatest cause of early mortality and remains a major problem thereafter. Increased rates of malignancy and cardiovascular disease are additional important long term sequelae. This review focuses on the complications associated with the immunosuppressive therapies most commonly used to treat ANCA-associated vasculitis, and considers prophylactic and monitoring strategies to minimize these risks. Achieving a balance between immunosuppression to reduce relapse risk and minimizing the adverse effects associated with therapy has become key. The contribution of glucocorticoids to treatment toxicity is increasingly being recognized, and future therapeutic strategies must concentrate on glucocorticoid minimization or sparing strategies. Development of robust predictors of an individual's future clinical course is needed in order to individually tailor treatment regimens.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Smith R. Complications of therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2020. PMID: 31967652. doi:10.1093/rheumatology/kez618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。